This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xia, Q. Articles by Rodriguez, R. Search for Related Content PubMed PubMed Citation Articles by Xia, Q. Articles by Rodriguez, R.

Chronic Administration of Valproic Acid Inhibits Prostate Cancer Cell Growth In vitro and In vivo

¹ Department of Urology, Shandong Provincial Hospital, Jinan, People's Republic of China; ² James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; and ³ Department of Urology, Chang Gung Memorial Hospital and Graduate Institute of Clinical Medical Sciences, Chang Gung University Taipei, Taiwan

Requests for reprints: Ronald Rodriguez, James Buchanan Brady Urological Institute, Johns Hopkins Hospital, 600 North Wolfe Street, Marburg 205, Baltimore, MD 21287. Phone: 410-614-6662; Fax: 443-287-1010; E-mail: rrodrig{at}jhmi.edu.

Valproic acid (VPA) is an established drug in the long-term therapy of seizure disorders. Recently, VPA has been associated with anticancer activity, an effect thought to be mediated through the inhibition of cellular histone deacetylase 1. We investigated the effect of various doses of VPA (0, 1.2, and 5.0 mmol/L) administered either acutely or chronically on histone acetylation, p21 gene expression, androgen receptor expression, prostate-specific antigen (PSA) expression, and cell survival and proliferation in prostate cancer cell lines. We also studied the effect of chronic VPA on tumor xenograft growth in vivo. Our results show that acute treatment (3 days) VPA can increase net histone H3 acetylation and up-regulate p21, AR, and cytosolic PSA expression. Interestingly, the effects on AR and PSA are reversed with chronic teatment. In addition, acute VPA reduces cell survival but has no effect on the subsequent proliferation of surviving cells following drug withdrawal. However, when VPA is chronically administered (10-14 days) to prostate cancer cells, even lower doses of VPA result in marked decreases in the net proliferation rate, correlating with increased caspase-2 and caspase-3 activation. These effects are evident in both androgen receptor-positive (LNCaP and C4-2) and androgen receptor-negative (DU145 and PC3) prostate cancer cells. Moreover, chronic VPA treatment results in statistically significant reduction of tumor xenograft growth in vivo. We conclude that acute treatment has nominal effects on prostate cancer cell survival and proliferation, but chronic VPA results in profound decreases in proliferation, independently of androgen regulation. (Cancer Res 2006; 66(14): 7237-44)

This article has been cited by other articles:

				M. S.Q. Kortenhorst, S. Isharwal, P. J. van Diest, W. H. Chowdhury, C. Marlow, M. A. Carducci, R. Rodriguez, and R. W. Veltri Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo Mol. Cancer Ther., April 1, 2009; 8(4): 802 - 808. [Abstract] [Full Text] [PDF]

				M. S.Q. Kortenhorst, M. Zahurak, S. Shabbeer, S. Kachhap, N. Galloway, G. Parmigiani, H. M.W. Verheul, and M. A. Carducci A Multiple-Loop, Double-Cube Microarray Design Applied to Prostate Cancer Cell Lines with Variable Sensitivity to Histone Deacetylase Inhibitors Clin. Cancer Res., November 1, 2008; 14(21): 6886 - 6894. [Abstract] [Full Text] [PDF]

				S. Sami, N. Hoti, H.-M. Xu, Z. Shen, and X. Huang Valproic Acid Inhibits the Growth of Cervical Cancer both In Vitro and In Vivo J. Biochem., September 1, 2008; 144(3): 357 - 362. [Abstract] [Full Text] [PDF]

				A. Valentini, M. Biancolella, F. Amati, P. Gravina, R. Miano, G. Chillemi, A. Farcomeni, S. Bueno, G. Vespasiani, A. Desideri, et al. Valproic Acid Induces Neuroendocrine Differentiation and UGT2B7 Up-Regulation in Human Prostate Carcinoma Cell Line Drug Metab. Dispos., June 1, 2007; 35(6): 968 - 972. [Abstract] [Full Text] [PDF]

				H. E. Carraway and S. D. Gore Addition of Histone Deacetylase Inhibitors in Combination Therapy J. Clin. Oncol., May 20, 2007; 25(15): 1955 - 1956. [Full Text] [PDF]

				C.-L. Chen, J. Sung, M. Cohen, W. H. Chowdhury, M. D. Sachs, Y. Li, Y. Lakshmanan, B. Y. M. Yung, S. E. Lupold, and R. Rodriguez Valproic Acid Inhibits Invasiveness in Bladder Cancer but Not in Prostate Cancer Cells J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 533 - 542. [Abstract] [Full Text] [PDF]